Top Warren Buffett Stocks To Invest In Right Now

Tell us how you really feel, Mr. Buffett.

The price of bitcoin took a dive after Warren Buffett renewed his criticism of the cryptocurrency even comparing it to rat poison.

Bitcoin had been closing in on $10,000, but it fell nearly 6% Sunday and was down another 2% Monday to just over $9,300.

Buffett, the CEO of Berkshire Hathaway (BRKB), has been a bitcoin bear for years. He has often compared the cryptocurrency to gold, saying that both assets are strictly speculative and don’t produce earnings and dividends like stocks do.

Before the Berkshire annual meeting on Saturday, Buffett told CNBC that bitcoin was “probably rat poison squared.”

During the meeting itself, Buffett joked that “if you had bought gold at the time of Christ and you figure the compound rate on it, it’s a couple tenths of a percent.” What Buffett was saying about bitcoin was that you can buy it, but it will never produce anything of value.

He also responded to a question from the audience about bitcoin by saying that it and other crytpocurrencies “will come to bad endings.”

Top Warren Buffett Stocks To Invest In Right Now: Ultralife Corporation(ULBI)

Advisors’ Opinion:

  • [By Shane Hupp]

    Polar Power (NASDAQ: POLA) and Ultralife (NASDAQ:ULBI) are both small-cap utilities companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends and valuation.

Top Warren Buffett Stocks To Invest In Right Now: United Fire Group, Inc(UFCS)

Advisors’ Opinion:

  • [By Shane Hupp]

    United Fire & Casualty (NASDAQ:UFCS) shares hit a new 52-week high and low during mid-day trading on Friday . The stock traded as low as $53.47 and last traded at $53.26, with a volume of 1018 shares trading hands. The stock had previously closed at $51.84.

  • [By Lee Jackson]

    United Fire Group Inc. (NASDAQ: UFCS) was downgraded to hold from buy at Sandler ONeill. The 52-week trading range for the shares has been $38.95 to $58.46. The stock closed Monday at $56, so this could be another valuation call.

  • [By Max Byerly]

    Get a free copy of the Zacks research report on United Fire Group (UFCS)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Joseph Griffin]

    Earnest Partners LLC grew its stake in shares of United Fire Group, Inc. (NASDAQ:UFCS) by 2.6% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,449,353 shares of the insurance provider’s stock after acquiring an additional 36,932 shares during the quarter. Earnest Partners LLC owned about 0.06% of United Fire Group worth $69,366,000 as of its most recent SEC filing.

  • [By Stephan Byrd]

    United Fire Group (NASDAQ:UFCS) was downgraded by stock analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a research note issued to investors on Friday.

  • [By Shane Hupp]

    Shares of United Fire & Casualty (NASDAQ:UFCS) hit a new 52-week high and low during trading on Thursday following a dividend announcement from the company. The company traded as low as $52.90 and last traded at $52.61, with a volume of 2181 shares trading hands. The stock had previously closed at $51.78.

Top Warren Buffett Stocks To Invest In Right Now: Ultragenyx Pharmaceutical Inc.(RARE)

Advisors’ Opinion:

  • [By Chris Lange]

    Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) is expected to report Phase 2 data from all its tumor-induced osteomalacia patients. Shares of Ultragenyx closed Friday at $76.87, in a 52-week range of $41.67 to $86.10 and with a consensus analyst target of $68.74.

  • [By Shane Hupp]

    These are some of the media headlines that may have effected Accern’s scoring:

    Get Ultragenyx Pharmaceutical alerts:

    Burosumab Improves Outcomes in Children with XLH in Phase 2 Trial (raredr.com) RARE Stock Is on the Verge of Breaking Out Toward Higher Prices (profitconfidential.com) Burosumab may benefit children with X-linked hypophosphatemia (medicalxpress.com) A Look Inside the Quant Data For Ultragenyx Pharmaceutical Inc. (NasdaqGS:RARE) (parkcitycaller.com) Ultragenyx Pharmaceutical Inc. (RARE)- Stock in the Trader’s Radar (nasdaqfortune.com)

    A number of research firms have recently weighed in on RARE. ValuEngine raised Ultragenyx Pharmaceutical from a “hold” rating to a “buy” rating in a report on Saturday. BidaskClub raised Ultragenyx Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 19th. Barclays raised Ultragenyx Pharmaceutical from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $62.00 to $74.00 in a report on Friday, May 11th. Goldman Sachs Group began coverage on Ultragenyx Pharmaceutical in a report on Thursday, May 10th. They set a “neutral” rating and a $63.00 target price for the company. Finally, Zacks Investment Research downgraded Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a report on Tuesday, January 30th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $70.06.

  • [By Todd Campbell]

    A Genentech alumnus, Conner was previously vice president of clinical science at Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biotech that has successfully developed therapies for rare and ultrarare diseases. Prior to that, he was senior medical director at BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), another biotech company that’s successfully developed drugs for rare diseases.

  • [By Joseph Griffin]

    BidaskClub upgraded shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) from a hold rating to a buy rating in a report released on Monday.

    A number of other brokerages have also recently weighed in on RARE. JPMorgan Chase restated an overweight rating and issued a $66.00 price objective (down from $68.00) on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, February 21st. Evercore ISI upgraded shares of Ultragenyx Pharmaceutical from an in-line rating to an outperform rating in a research note on Monday, January 22nd. Stifel Nicolaus restated a buy rating and issued a $74.00 price objective (down from $85.00) on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, February 21st. ValuEngine upgraded shares of Ultragenyx Pharmaceutical from a sell rating to a hold rating in a research note on Wednesday, April 4th. Finally, Wedbush reiterated a positive rating and set a $71.00 target price (up from $64.00) on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, April 18th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and sixteen have issued a buy rating to the company. Ultragenyx Pharmaceutical presently has a consensus rating of Buy and an average price target of $69.76.

Top Warren Buffett Stocks To Invest In Right Now: Lexington Realty Trust(LXP)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Lexington Realty Trust (NYSE:LXP) is scheduled to be releasing its earnings data before the market opens on Tuesday, May 8th. Analysts expect Lexington Realty Trust to post earnings of $0.06 per share for the quarter. Lexington Realty Trust has set its FY18 guidance at $0.95-0.98 EPS.

  • [By Max Byerly]

    ValuEngine upgraded shares of Lexington Realty Trust (NYSE:LXP) from a strong sell rating to a sell rating in a research note released on Friday.

    Several other brokerages have also weighed in on LXP. Stifel Nicolaus lowered Lexington Realty Trust from a hold rating to a sell rating and cut their price target for the company from $8.50 to $7.00 in a research note on Tuesday, May 8th. Zacks Investment Research upgraded Lexington Realty Trust from a sell rating to a hold rating in a research note on Saturday, May 12th. Barclays cut their price target on Lexington Realty Trust from $10.00 to $9.00 and set an underweight rating for the company in a research note on Tuesday, March 20th. Wells Fargo & Co cut their price target on Lexington Realty Trust from $11.00 to $9.00 and set a market perform rating for the company in a research note on Monday, March 19th. Finally, JPMorgan Chase & Co. lowered their price objective on Lexington Realty Trust from $10.00 to $9.00 and set a neutral rating on the stock in a report on Tuesday, April 10th. Four equities research analysts have rated the stock with a sell rating and eight have assigned a hold rating to the stock. Lexington Realty Trust has a consensus rating of Hold and an average price target of $9.68.

  • [By Ethan Ryder]

    Lexington Realty Trust (NYSE:LXP) was downgraded by equities researchers at Stifel Nicolaus from a “hold” rating to a “sell” rating in a note issued to investors on Tuesday, MarketBeat reports. They currently have a $7.00 target price on the real estate investment trust’s stock, down from their previous target price of $8.50. Stifel Nicolaus’ price target suggests a potential downside of 15.66% from the stock’s current price.

Leave a Reply

Your email address will not be published. Required fields are marked *